Management of Pelvic Endometriosis with a GnRH Analogue

Abstract

Pelvic endometriosis remains a difficult gynaecological problem to manage and yet the progression of the disease can be very detrimental to the health of the patients. Surgical treatment often involves removal of the reproductive as well as the hormonal functions of the patient. With the discovery of GnRH analogues ability to induce reversible suppression of the hypothalamic-pituitary-ovarian axis, it becomes possible to produce a hypoestrogenic state which allows regression of the disease. This paper reports on a Phase III clinical trial on the use of buserelin (Hoechst China Ltd) in the management of patients with severe pelvic endometriosis.